Table 1. Demographic and baseline characteristics of the study participant.
| Variable | High HGI (n = 269) | Low HGI (n = 199) | P-value |
|---|---|---|---|
| Age, years | 56±13 | 59±12 | 0.05 |
| Male Sex, n (%) | 154 (57.2) | 114 (57.3) | 1.00 |
| Body weight (kg) | 69±15 | 68±11 | 0.340 |
| Body mass index (kg/m2) | 26.2±4.4 | 25.8±3.5 | 0.415 |
| HbA1c (%) | 9.5±1.9 (80±21mmol/mol) | 7.5±1.0 (58±11mmol/mol) | <0.001 |
| FPG (mg/dL) | 161±57 (8.9±3.1mmol/L) | 160±46 (8.8±2.5mmol/L) | 0.848 |
| Creatinine (mg/dL) | 0.9±0.4 (80±35μmol/L) | 1.0±0.4 (88±35μmol/L) | 0.161 |
| Systolic BP (mmHg) | 135±19 | 132±18 | 0.157 |
| Diastolic BP (mmHg) | 80±11 | 78±10 | 0.168 |
| No. of glucose-lowering background drugs |
1.5±0.9 | 1.4±0.8 | 0.489 |
| Metformin, n (%) | 173 (64.3) | 129 (64.8) | 0.922 |
| Sulfonylurea, n (%) | 146 (54.3) | 98 (49.2) | 0.304 |
| Insulin, n (%) | 20 (7.4) | 4 (2.0) | 0.01 |
| Meglitinide, n (%) | 8 (3.0) | 3 (1.5) | 0.368 |
| AGI, n (%) | 30 (11.2) | 25 (12.6) | 0.665 |
| Thiazolidinedione, n (%) | 36 (13.4) | 25 (12.6) | 0.890 |
Continuous variables are expressed as mean ± SD.
Categorical data are presented as numbers (percentages).
Abbreviations: AGI, α-glucosidase inhibitor; BP, blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HGI, hemoglobin glycation index.